EVT302 has failed to meet the primary endpoint of a Phase IIb trial in Alzheimer’s disease. Partner Roche will now fully evaluate all secondary endpoints to determine EVT302’s future. We have lowered EVT302’s probability of success to 5% (from 20%), reducing our valuation to €486m. Despite this pipeline disappointment, we continue to believe that Evotec remains well placed to accelerate growth, with the Sanofi deal providing capacity, guaranteed future revenues and enha
02 Jul 2015
Growth drivers intact despite EVT302 setback
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Growth drivers intact despite EVT302 setback
EVT302 has failed to meet the primary endpoint of a Phase IIb trial in Alzheimer’s disease. Partner Roche will now fully evaluate all secondary endpoints to determine EVT302’s future. We have lowered EVT302’s probability of success to 5% (from 20%), reducing our valuation to €486m. Despite this pipeline disappointment, we continue to believe that Evotec remains well placed to accelerate growth, with the Sanofi deal providing capacity, guaranteed future revenues and enha